Our development portfolio includes novel oncology and supportive care product candidates.

Registration
Phase 3
Phase 2
Phase 1
Pre-Clinical
Discovery
Compound
Indication
Phase
Rolapitant(IV)
Anti-TIM-3/PD-1 antibody
Anti-LAG-3/PD-1 antibody

* In collaboration with SARC, the Sarcoma Alliance for Research through Collaboration

Upon successful development and regulatory approval of any of our product candidates we intend to make them available to cancer patients in North America, Europe and China through our own commercialization efforts and to establish a network of licensees and distributors in other geographic areas.


Clinical Trials

The links below will provide you with information regarding TESARO's ongoing clinical trials.

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue